Xencor, Inc.

XNCR

NASDAQ

Healthcare

Biotechnology

Pasadena, CA, US250 employeesxencor.com

$12.79

+0.27(2.1%)

52W $7.00 – $18.14

AI-generated from 10-K FY2025 filed Feb 24, 2026

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and auto...

Revenue breakdown: Milestone (81.3%), Collaboration (14.6%), License (4.1%).

$938MMkt Cap

$124MRev TTM

-$91MNI TTM

-9.7xP/E TTM

Latest Earnings

10-K

FY FY2025Feb 24, 2026

10-K for FY2025 was filed on 2026-02-25. AI summary is not available yet.

Read full analysis View SEC Filing

What Changed Recently

Material AgreementMar 8, 2026

. Termination of a Material Definitive Agreement On March 4, 2026, Xencor, Inc. (the “Company”) received a notice of termination of an Amended and Restated Coll

View filing →

Regulation FDMar 3, 2026

of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”

View filing →

Financial ResultsFeb 24, 2026

. Results of Operations and Financial Condition” of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deem

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Revenue by Segment

Milestone81.3%($337M)

Collaboration14.6%($61M)

License4.1%($17M)

Peer Companies

Company	Price	Change	Market Cap	P/E
TNGXTango Therapeutics, Inc.	$21.66	+2.07%	$2.5B	-21.7
KODKodiak Sciences Inc.	$40.55	-5.28%	$2.1B	-5.4
ANABAnaptysBio, Inc.	$57.98	+2.20%	$1.7B	-131.7
NKTRNektar Therapeutics	$77.01	+1.72%	$1.6B	-9.2
MNMDMind Medicine (MindMed) I...	$20.65	+0.24%	$1.6B	-8.8
OCSOculis Holding AG	$26.48	-2.03%	$1.5B	-11.0
NRIXNurix Therapeutics, Inc.	$15.51	+0.16%	$1.3B	-5.3
URGNUroGen Pharma Ltd.	$18.84	-0.53%	$917M	-5.5

Company Profile

CIK0001326732

ISINUS98401F1057

CUSIP98401F105

Phone626 305 5900

Address111 West Lemon Avenue, Pasadena, CA, 91016, US

SEC EDGAR